Julie Mehta

Hi, thank you for the opportunity. So , my first question pertains to, we have added recently 3 lines, and we have another one underway in our injectable facility. So , how is it 3 versus post capacity looking like, capacity utilization?

And sir, my next question is that since we are planning to file GLP-1 molecule in the emerging markets, so since it is a highly competitive space and with Mounjaro coming in and Semaglutide will come in March ‘26, like post patent expiry, there will be a huge inflow of players at that point. So, what is our thought behind entering such a competitive space and that to a new one?

I just drop in my last question. So , can you just throw some light on any key products that w e are looking at launching in the next two years and any guidance as to how it can meaningfully contribute to us?